Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H25N9O6S.2Na |
Molecular Weight | 649.589 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].COC1=CC=CC=C1OC2=C(OCCO)N=C(N=C2[N-]S(=O)(=O)C3=CC=C(C=N3)C(C)C)C4=CC(=NC=C4)C5=NN=N[N-]5
InChI
InChIKey=LJEMFZYMXONDDJ-UHFFFAOYSA-N
InChI=1S/C27H25N9O6S.2Na/c1-16(2)18-8-9-22(29-15-18)43(38,39)34-26-23(42-21-7-5-4-6-20(21)40-3)27(41-13-12-37)31-24(30-26)17-10-11-28-19(14-17)25-32-35-36-33-25;;/h4-11,14-16,37H,12-13H2,1-3H3;;/q-2;2*+1
Molecular Formula | Na |
Molecular Weight | 22.98976928 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C27H26N9O6S |
Molecular Weight | 604.617 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15596026Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15055997 | https://clinicaltrials.gov/ct2/show/NCT00524433 | https://www.ncbi.nlm.nih.gov/pubmed/14632537 | https://clinicaltrials.gov/ct2/show/NCT01077297 | https://www.ncbi.nlm.nih.gov/pubmed/22474738
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15596026
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15055997 | https://clinicaltrials.gov/ct2/show/NCT00524433 | https://www.ncbi.nlm.nih.gov/pubmed/14632537 | https://clinicaltrials.gov/ct2/show/NCT01077297 | https://www.ncbi.nlm.nih.gov/pubmed/22474738
Tezosentan (Veletri; Ro 61–0612) is a dual endothelin receptor antagonist that has been shown to improve cardiac output, decrease pulmonary capillary wedge pressure, and reduce pulmonary and systemic vascular resistance in initial clinical studies in acutely decompensated heart failure. Tezosentan is a water-soluble ET-1 receptor antagonist with high affinity to both ETA and ETB receptors but greater potency for the ETA receptor subtype. Clinical studies demonstrated mixed results for Tezosentan regarding its efficacy and tolerability in the management of decompensated heart failure. The side effects of Tezosentan include a headache, nausea, and hypotension.
Originator
Sources: https://encrypted.google.com/patents/WO1996019459A1
Curator's Comment: # F. Hoffmann-La Roche Ag
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL252 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15055997 |
23.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
50th Annual scientific sessions of the American college of cardiology. | 2001 Apr 10 |
|
Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets. | 2001 Dec |
|
Role of endogenous endothelin on coronary reflow after cardioplegic arrest. | 2001 Dec |
|
Endothelin receptor blockade improves oxygenation in contralateral TRAM flap tissue in pigs. | 2001 Jul |
|
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. | 2001 Jun |
|
Tezosentan inhibits both equinatoxin II and endotelin-1 induced contractions of isolated porcine coronary artery in a similar way. | 2002 Aug |
|
Endogenous endothelin increases gallbladder tone and leads to acute cholecystitis in the Australian possum. | 2004 Feb |
|
Role of endothelin-1 and thromboxane A2 in the pulmonary hypertension induced by heparin-protamine interaction in anesthetized dogs. | 2004 Jan |
|
Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock. | 2004 May |
|
Renal blood flow in sepsis. | 2005 Aug |
|
Endothelin-1 causes systemic vasodilatation in anaesthetised turtles (Trachemys scripta) through activation of ETB-receptors. | 2005 Oct |
|
The role of indomethacin and tezosentan on renal effects induced by Bothrops moojeni Lys49 myotoxin I. | 2006 Jun 15 |
|
NO and prostanoids blunt endothelin-mediated coronary vasoconstrictor influence in exercising swine. | 2006 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01077297
single infusion of tezosentan 5mg/h over 30 min corresponding to 2.5 mg
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22474738
Aortic valves were obtained from 16 patients at the time of aortic valve replacement surgery. After surgical removal, each valve was divided approximately into 15 pieces. Valve pieces (4 mm diameter) of normal and sclerotic aortic valves were cultured in αMEM (Gibco, Paisley, UK), supplemented with 10% heat-inactivated fetal bovine serum (FBS; Autogen Bioclear, Wiltshire, UK), 20 mM HEPES (Gibco) 100 U/ml penicillin, 0.1 mg/ml streptomycin (Gibco) and 2 mM L-glutamine (Gibco) at 37°C in 5% CO2 and 95% air. For the measurement of radioactivity in cell culture experiments, valve pieces from two normal patients (resulting in 30 valve pieces) as well as six stenotic patients (resulting in 90 valve pieces) were inserted into the 24-well plates, the medium was changed, and the test drugs (125I-ET-1, 10 nmol/l; ET-1, 100 µmol/l; tezosentan, 10 nmol/l) were added on the second day of culture. After 20 min and 3 h of incubation, the valves were washed three times with DPBS (BioWhittaker, Lonza, Belgium). Radioactivity was measured using a Wallac Multigamma counter (Wallac, Turku, Finland) and results were expressed as counts per minute.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:24:37 GMT 2025
by
admin
on
Mon Mar 31 21:24:37 GMT 2025
|
Record UNII |
2Q53CXJ1D6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m10670
Created by
admin on Mon Mar 31 21:24:37 GMT 2025 , Edited by admin on Mon Mar 31 21:24:37 GMT 2025
|
PRIMARY | Merck Index | ||
|
2Q53CXJ1D6
Created by
admin on Mon Mar 31 21:24:37 GMT 2025 , Edited by admin on Mon Mar 31 21:24:37 GMT 2025
|
PRIMARY | |||
|
6918475
Created by
admin on Mon Mar 31 21:24:37 GMT 2025 , Edited by admin on Mon Mar 31 21:24:37 GMT 2025
|
PRIMARY | |||
|
180384-58-1
Created by
admin on Mon Mar 31 21:24:37 GMT 2025 , Edited by admin on Mon Mar 31 21:24:37 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |